Dallas, TX, April 21, 2016 --(PR.com
)-- Bone Solutions Inc., is positioned to launch its FDA approved OsteoCrete magnesium technology this summer for the domestic and international extremities markets. Drew Diaz, Bone Solution’s CEO, stated, “We are extremely pleased to be positioned with Next Health for the launch of our much awaited magnesium based technology. OsteoCrete will be the first product in the marketplace utilizing magnesium for its Orthobiologic platform.”
Next Health is a Dallas based orthopedic distributor with a strong foot print in multiple states throughout the United States. This new partnership will bring both the strength of a strong distribution model along with an exciting and disruptive technology in the Orthobiologic marketplace. Kent Sohosky, Next Health President, “We are very excited to be partnering with such an innovative company as Bone Solutions. Next Health looks forward to driving the market adoption of OsteoCrete throughout the United Sates.”
BSI will begin the FDA process for the Spinal, Dental and Craniomaxillofacial markets once OsteoCrete is launched in the general orthopedic and extremities market this year. The company believes this technology can open the door for many new applications and techniques in the orthopedic market, creating potential new large markets for Bone Solutions Inc. products.
The company also noted that to date, a surge in biomaterials capable of treating orthopedic injuries has led to a Multitude of products such as bone cements to attach various objects to bone, and bone void fillers capable of treating bone fractures and other bone defects.